Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (10749)	3/1/2004 3:32:55 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 52153

yeah, they need to get market share in a hurry. thanks for the review of CRIS. as I said, science has always been top-"notch". nice to hear that the company is different, but the projects are nonetheless very old. perhaps you read criticism in that. there is none.

To: NeuroInvestment who wrote (10749)	3/1/2004 3:33:05 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Thanks for the CRIS update, Harry. On SEPR, resubmitting the NDA is I believe just shorthand for resubmitting with answers to the questions raised by the FDA in their approvable letter. These answers are such that they will almost certainly fall into the "Class 1" resubmission category, with a two-month clock on the FDA. Thus adding the 1-3 months that SEPR says they will need for their response, we get 3-5 months before approval. That puts us in the May-July time frame by my reckoning - i.e., 2Q-3Q. SEPR promised to tighten up their 1-3 month response window once they have spoken with the FDA later this month. Peter